While PARP1 trapping and its cytotoxic effects are desirable in cancer treatment, this could be a limitation when planning to use PARPi in non-oncological conditions [144] such as ischemia-reperfusion injury [145] or neurodegenerative diseases. The gene discussed is PARP1; the disease is cancer.